logo-loader
viewTherapix Biosciences Ltd

FSD Pharma and medical cannabis company Therapix Biosciences sign letter of intent in $48M tie-up

The companies are combining two complementary businesses focused on the research and development of cannabinoid treatments

A physician holding up a cannabis plant
Therapix in April announced positive results from a mid-stage trial of its cannabinoid-based drug to treat Tourette syndrome, a nervous system disorder

Canada’s FSD Pharma Inc (CSE:HUGE, OTCMKTS:FSDDF) signed a letter of intent (LOI) Wednesday to acquire Therapix Biosciences Ltd (NASDAQ:TRPX), an Israeli clinical-stage pharma company focusing on the development of cannabinoid-based treatments, for approximately $48 million in stock.

The shareholders of Therapix will receive FSD stock upon closing of the transaction. The letter of intent will be superseded by a definitive agreement, which the companies intend to execute within 30 days.  The deal is expected to be completed by the first quarter.

Investors sent Therapix stock up 11.1% to $6 in premarket trade Wednesday, while FSD Pharma closed 16.08% higher to $0.43 on Tuesday.

"We are excited to join FSD Pharma to be part of one of the fastest growing, most forward-thinking companies in this sector," said Therapix chairman Ascher Shmulewitz. "Our combined resources and highly competent scientific and business leadership teams, position the combined entity well to execute upon our shared vision to deliver groundbreaking, proprietary cannabinoid platform technologies to both the professional and retail markets globally. As a result, we have suspended all negotiations with Cure Pharmaceutical Holding Corp."

READ: FSD Pharma and Therapix Biosciences in $48M deal to form medical cannabis company

Therapix in April announced positive results from a mid-stage trial of its cannabinoid-based drug to treat Tourette syndrome, a nervous system disorder involving repetitive movements or unwanted sounds.

Raza Bokhari, Director of FSD Pharma and Chairman of the M&A committee saw the intended acquisition of Therapix Biosciences as a “pivotal step” in the evolution of the company by entering the “high-value medical cannabis market."

"With this acquisition, FSD Pharma is signaling our commitment to furthering very high-value pharmaceutical R&D clinical programs centered on cannabinoid molecules,” said Bokhari.

FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations. The company is based in Cobourg, Ontario.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Therapix Biosciences Ltd

Price: 0.4771 USD

NASDAQ:TRPX
Market: NASDAQ
Market Cap: $2.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: PetVivo preparing to bring their lead medical device Kush to...

PetVivo (OTCQB: PETV) CEO John Lai joined Steve Darling from Proactive to discuss the company that is developing a treatment for osteoarthritis is horses and dogs. The company’s lead medical device is called Kush and according to PetVivo it mimics cartilage. Lai tells Proactive about the size...

43 minutes ago

2 min read